Key Takeaways:
Novartis paused eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders after three patients died from a severe immune response.
The Swiss drugmaker halted the studies in late August after learning of the fatal cases, the Wall Street Journal reported Tuesday. A Novartis spokesman described the immune response as a known safety risk in CAR-T therapies, the Journal said.
The experimental treatment, called rap-cel, modifies a patient's own immune cells to recognize a specific target and destroy diseased cells. CAR-T emerged as a breakthrough cancer treatment, and researchers have been exploring its use against autoimmune and neurological conditions. It wasn't immediately clear when the three deaths occurred. Novartis said it is conducting a full review of the safety events, working with the independent boards overseeing each paused study and sharing what it knows with regulators.
Bristol-Myers Squibb also paused similar trials of its own CAR-T treatment in autoimmune disorders as a precautionary measure. Because two major drugmakers suspended comparable programs around the same time, the moves raise broader questions about the safety profile of CAR-T therapies as they expand beyond oncology.
The pause could extend approval timelines and raise development costs for Novartis's cell therapy program, a closely watched expansion beyond its oncology base. Novartis, with a market value of about $289.6 billion, trades at $152.06, roughly 16.5 percent above the $130.52 intrinsic value estimate from GuruFocus, with a price-to-earnings ratio of 22.94 times against a five-year median of 16.98 times. The company's dividend yield of 3.12 percent and payout ratio of 71 percent remain supported by stable earnings, though the clinical setback adds uncertainty to its growth pipeline.
The safety review's outcome and any regulatory action from the US Food and Drug Administration or the European Medicines Agency will determine how quickly the program can resume. Investors will watch for updates from Novartis and the independent safety boards in the coming weeks, as the sector's autoimmune cell therapy ambitions hinge on whether the fatal immune responses prove manageable.
This article is for informational purposes only and does not constitute investment advice.
